Burr Hole Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

A burr hole is a circular perforation in the skull, typically 15–25 mm in diameter, made using a high-speed neurosurgical drill (perforator and burr). Unlike a craniotomy — where a large bone flap is removed and later replaced — a burr hole creates a permanent small opening that allows access to the brain, its coverings, or the ventricular system through a minimally invasive route.

Burr hole surgery spans a broad spectrum of indications, ranging from emergency life-saving interventions (draining a rapidly expanding blood clot) to elective precision procedures (implanting a deep brain stimulator electrode with millimetre accuracy). The common thread is that a small opening in the skull provides sufficient access to achieve the therapeutic goal without the morbidity of a full craniotomy.

The procedure can be performed under local anaesthesia and sedation (particularly for twist-drill craniostomy in frail elderly patients with chronic subdural haematoma, or for awake deep brain stimulation implantation) or under general anaesthesia. Operative duration ranges from 30 minutes for a simple cSDH drainage to 4–8 hours for bilateral deep brain stimulator implantation with microelectrode recording and intraoperative test stimulation.

Modern burr hole procedures are guided by frameless stereotactic neuronavigation or frame-based stereotaxis (for biopsy and DBS), endoscopic visualisation (for endoscopic third ventriculostomy), microelectrode recording (for DBS), and real-time fluoroscopy (for ventriculoperitoneal shunt insertion). These technologies have greatly improved the precision, safety, and reproducibility of burr hole surgery over the past three decades.

The majority of burr hole procedures are performed by consultant neurosurgeons in specialist neurosurgical units. Some emergency procedures — particularly burr hole evacuation of extradural haematoma — may be performed by trained general or trauma surgeons in emergency settings where neurosurgical transfer is not possible within a safe time window.

Burr hole surgery is employed across a wide range of neurological and neurosurgical conditions:

• Chronic Subdural Haematoma (cSDH): The commonest elective neurosurgical indication for burr holes. A collection of liquefied and membrane-encapsulated blood between the dura mater and brain surface, typically presenting with progressive headache, cognitive decline, hemiparesis, or reduced consciousness in elderly patients (often after seemingly minor head injury). Burr hole craniostomy with drain placement is the standard surgical treatment, achieving immediate decompression in over 85% of cases.
• Acute Extradural Haematoma (EDH): A neurosurgical emergency, typically from a middle meningeal artery tear after temporal skull fracture. Emergency burr hole (or craniotomy) is life-saving when a patient presents with the classic lucid interval followed by rapid neurological deterioration. Outcome is critically dependent on speed of decompression.
• Acute Subdural Haematoma (SDH): While large acute SDHs typically require formal craniotomy, selected thin acute-on-chronic SDHs or sub-acute SDHs may be adequately drained through burr holes, avoiding the morbidity of craniotomy in frail patients.
• Hydrocephalus — Endoscopic Third Ventriculostomy (ETV): A burr hole provides access for a rigid neuroendoscope to be passed through the cerebral cortex and ventricle to create a stoma (opening) in the floor of the third ventricle, bypassing the CSF obstruction in non-communicating (obstructive) hydrocephalus. ETV avoids the need for a shunt and its associated long-term complications.
• Stereotactic Brain Biopsy: A small burr hole allows passage of a stereotactic biopsy needle under frame-based or frameless guidance to obtain tissue from deep or eloquent brain lesions for histopathological diagnosis when open resection is not appropriate.
• Deep Brain Stimulator (DBS) Lead Implantation: Two burr holes (one per side for bilateral implantation) allow passage of DBS leads to targets including the subthalamic nucleus (STN-DBS for Parkinson's disease), globus pallidus interna (GPi-DBS for dystonia), and the ventral intermediate nucleus of the thalamus (Vim-DBS for essential tremor). Microelectrode recording through the burr hole provides physiological target confirmation before final lead placement.
• Ommaya Reservoir Placement: A burr hole allows subcutaneous reservoir implantation connected to a catheter in the lateral ventricle, enabling repeated intrathecal drug delivery (chemotherapy for CNS lymphoma or leptomeningeal carcinomatosis, antifungal agents) or CSF sampling without repeated lumbar puncture.
• ICP Monitoring Bolt Placement: A small burr hole allows placement of a parenchymal ICP monitoring bolt (Camino or Codman device) for continuous intracranial pressure monitoring in traumatic brain injury, severe SAH, or other causes of raised ICP.

The decision to proceed with burr hole surgery — and the choice of specific procedure — depends on the diagnosis, clinical urgency, patient factors, and available alternatives.

For chronic subdural haematoma: Surgery is indicated when cSDH produces neurological symptoms (headache, drowsiness, focal deficits), significant mass effect or midline shift on imaging, or progressive haematoma growth on serial CT. Asymptomatic, small, or stable cSDHs in elderly patients may be managed conservatively with serial CT monitoring and optimisation of anticoagulation. The NIHR CSDH trial (UK, published 2021) studied whether dexamethasone reduced the need for surgery in cSDH — it did not improve 6-month functional outcomes and increased adverse events including infection and hyperglycaemia; routine dexamethasone is not recommended for cSDH.

For ETV in hydrocephalus: ETV is most effective for obstructive (non-communicating) hydrocephalus, particularly aqueduct stenosis. The ETV Success Score (ETVSS) predicts procedural success based on patient age, aetiology, and prior shunt history. ETV is less effective in communicating hydrocephalus (where the primary problem is CSF reabsorption), in infants under 6 months, and in post-haemorrhagic or post-infectious hydrocephalus.

For DBS: Patient selection for deep brain stimulation requires a multidisciplinary assessment by movement disorder neurologists, neurosurgeons, neuropsychologists, and psychiatrists. DBS for Parkinson's disease is most effective in patients with significant L-DOPA-responsive motor fluctuations who retain good cognition and do not have prominent axial symptoms (falls, freezing, dysarthria) which DBS does not reliably address.

For frail or high-surgical-risk patients: Twist-drill craniostomy (a smaller, 5mm burr hole made with a twist drill under local anaesthesia at the bedside or in radiology) is an option for cSDH drainage in patients who cannot safely undergo general anaesthesia, offering a lower procedural risk at the cost of slightly higher recurrence rates.

Burr Hole Craniostomy for Chronic Subdural Haematoma: The standard surgical treatment for cSDH. One or two burr holes (typically at the frontal and parietal regions) are made under general or local anaesthesia. The dura is opened and the haematoma membrane punctured to release the liquid haematoma contents. A closed-system drain is left in the subdural space for 24–48 hours under strict aseptic conditions. The patient is typically nursed flat for 24 hours to encourage brain re-expansion. Success rate for haematoma resolution exceeds 85%, but recurrence within 3–6 months occurs in 10–20% of cases.

Middle Meningeal Artery (MMA) Embolisation: An emerging endovascular alternative and adjunct to surgery for cSDH. The MMA supplies the outer haematoma membrane; embolising it with particles or liquid embolic agents (Onyx) via a femoral artery approach starves the membrane of its blood supply, promoting haematoma resolution. Preliminary trials and meta-analyses show MMA embolisation reduces cSDH recurrence rates to 2–5% compared to 10–20% with surgery alone. The STEM trial (Barrow Neurological Institute) and UK EMBOLISE RCT are major ongoing studies comparing surgery alone versus surgery plus MMA embolisation and MMA embolisation alone for cSDH.

Twist-Drill Craniostomy: A 5mm opening made under local anaesthesia with a hand-held twist drill, suitable for cSDH drainage in frail patients or as an emergency bedside procedure. A flexible catheter is inserted and connected to a closed drainage system. The procedure is faster and safer in high-anaesthetic-risk patients but has a somewhat higher recurrence rate than formal burr hole craniostomy.

Endoscopic Third Ventriculostomy (ETV): A 6mm burr hole (typically right frontal, Kocher's point — 11cm posterior to the nasion, 3cm lateral to the midline) allows introduction of a rigid neuroendoscope through the cerebral cortex and foramen of Monro into the third ventricle. The floor of the third ventricle is perforated using a blunt stylet, balloon dilation, and confirmation of pulsatile CSF flow under endoscopic vision. The stoma allows CSF to bypass the aqueduct obstruction into the subarachnoid space.

Stereotactic Biopsy (Frame-Based and Frameless): Frame-based stereotaxis (Leksell or CRW frame) provides rigid, highly accurate (submillimetre) target localisation. Frameless biopsy uses neuronavigation registration to a preoperative MRI, allowing biopsy without the patient wearing a head frame overnight. Diagnostic yield exceeds 95% for enhancing lesions. A stereotactic biopsy needle is passed through the burr hole to the target, and multiple core specimens are taken and immediately assessed by frozen section histology to confirm adequacy before wound closure.

DBS Lead Implantation via Burr Holes: Under general anaesthesia or conscious sedation (for awake microelectrode recording), a single or split burr hole is made bilaterally. Microelectrode recording (MER) identifies the physiological target — characteristically irregular, high-frequency STN firing at 300–500 Hz for STN-DBS — before the permanent DBS lead is inserted. The lead is secured to the skull with a burr hole cap. A connecting extension cable runs subcutaneously to the implantable pulse generator (IPG) placed in a subclavicular or abdominal pocket under the same anaesthetic or in a staged second procedure.

Burr hole procedures offer several advantages over full craniotomy for appropriate indications:

• Minimally invasive approach: A 15–25mm skull opening causes substantially less surgical trauma than craniotomy, reducing blood loss, operative time, wound healing requirements, and postoperative pain. Many procedures can be performed as day cases or with 1–2 day hospital stays.
• Local anaesthesia feasibility: Twist-drill craniostomy for cSDH and awake DBS implantation can be safely and comfortably performed under local anaesthesia and light sedation, making surgery accessible to elderly and medically frail patients who would not tolerate general anaesthesia safely.
• High success rates for cSDH: Burr hole craniostomy achieves immediate neurological improvement in over 85% of cSDH patients. The majority experience rapid resolution of headache, cognitive improvement, and limb weakness within hours to days of surgery. The procedure takes 30–60 minutes and is associated with low intraoperative risk in experienced hands.
• ETV — shunt-free hydrocephalus management: Successful ETV eliminates the need for a ventriculoperitoneal (VP) shunt, avoiding the lifelong complications of shunt malfunction, shunt infection (2–5% per year), and shunt revision surgery. Long-term ETV success rates of 70–85% in appropriately selected patients (aqueduct stenosis, ETVSS above 70%) represent a significant quality-of-life benefit.
• DBS — transformative for movement disorders: STN-DBS for Parkinson's disease produces 40–60% improvements in UPDRS motor scores and 50–70% reduction in off-period duration, enabling reductions in dopaminergic medication and marked improvement in dyskinesia, tremor, and quality of life. GPi-DBS for generalised dystonia produces dramatic, often life-changing reductions in dystonic posturing and pain over weeks to months after implantation.

While burr hole surgery is less invasive than craniotomy, it carries important risks that vary by indication and procedure:

• Chronic subdural haematoma recurrence: The most common complication of cSDH surgery, occurring in 10–20% of patients within 3–6 months. Risk factors include anticoagulant or antiplatelet use, bilateral cSDH, large initial haematoma volume, and incomplete brain re-expansion. Reoperation or MMA embolisation may be required. Recurrence-prevention strategies include leaving a subdural drain for 48 hours, maintaining oral hydration to encourage brain expansion, and carefully timing anticoagulation restart.
• Intracerebral haemorrhage: Passage of any needle or catheter through the brain parenchyma carries a 1–2% risk of significant haemorrhage, which may require emergency craniotomy. Risk is higher in patients taking antiplatelet agents, with coagulopathy, or when targeting highly vascularised lesions at biopsy.
• Infection and meningitis: Burr hole procedures breach the natural protective barrier of the skull and dura, creating a route for ascending infection. Wound infection, meningitis, and ventriculitis are each estimated at 1–3%; stringent aseptic technique, perioperative antibiotics, and careful drain management minimise risk.
• Neurological deficit: Cortical or subcortical injury from needle passage, haemorrhage, or cortical collapse after cSDH drainage can produce new focal neurological deficits. The risk is approximately 1–5% depending on procedure complexity and patient factors.
• DBS-specific complications: Hardware-related complications include lead migration, lead fracture, and IPG infection (approximately 3–5% per system lifetime). Stimulation-related adverse effects include paraesthesia, dysarthria, and mood changes at certain electrode contact configurations, usually resolving with reprogramming. Intraoperative haemorrhage during lead insertion occurs in approximately 1–2% of implantations; symptomatic haemorrhage causing permanent deficit is seen in under 1%.
• ETV failure: Acute ETV failure from stoma closure may cause acute obstructive hydrocephalus and is a neurosurgical emergency. Chronic failure (stoma sealing) occurs in approximately 15–30% of patients over years and requires revision ETV or shunt insertion.

Recovery timelines and follow-up requirements vary significantly by procedure type:

After cSDH drainage: Patients are nursed with the head of bed flat for 24 hours and encouraged to maintain good oral fluid intake to promote brain re-expansion and haematoma space collapse. CT brain is repeated 24–48 hours postoperatively to assess haematoma resolution and confirm drain position. Neurological improvement is often rapid and dramatic. Most patients are discharged within 3–5 days. A follow-up CT at 4–6 weeks confirms continued resolution and identifies the 10–20% who experience recurrence requiring further treatment. Anticoagulation — if withheld for surgery — is typically restarted at 24–48 hours if the postoperative CT shows no haematoma re-accumulation and the indication for anticoagulation is strong (e.g., mechanical heart valve, atrial fibrillation with high CHA2DS2-VASc score).

After ETV: Hospital stay is typically 2–4 days. MRI brain (or CT cisternogram) at 1–3 months confirms ETV patency and ventricle size reduction. Regular follow-up is important because late ETV failure can be insidious; patients and carers must be educated on the symptoms of hydrocephalus recurrence (progressive headache, drowsiness, visual disturbance) and the need to seek urgent review.

After DBS implantation: DBS programming (adjustment of stimulation parameters — amplitude, frequency, pulse width, contact configuration) begins 2–4 weeks after implantation, after tissue swelling resolves. Multiple programming sessions over 3–6 months are typically needed to optimise stimulation parameters and gradually reduce dopaminergic medication in Parkinson's disease. The IPG battery lasts 3–5 years (non-rechargeable) or 10–15 years (rechargeable); IPG replacement is performed under local or general anaesthesia as a day case procedure.

After stereotactic biopsy: Most patients are observed overnight with neurological observations. If histology returns a malignant diagnosis, early referral to a neuro-oncology MDT is essential to plan radiotherapy, chemotherapy, or targeted therapy. For inflammatory or infectious diagnoses, appropriate medical treatment is initiated promptly.

Burr hole procedures are generally substantially less expensive than open craniotomy, owing to shorter operative times, less complex equipment requirements, and shorter hospital stays. However, cost varies considerably by procedure complexity and country:

• Chronic SDH drainage: In the United States, burr hole cSDH drainage with hospital stay typically costs USD 15,000–40,000 including surgery, anaesthesia, ICU or HDU stay, and imaging. In the United Kingdom NHS, this is covered at no cost to the patient; private costs are GBP 5,000–15,000. In India at accredited neurosurgical centres, total costs are typically INR 80,000–250,000 (USD 1,000–3,000), representing very significant savings for international patients.
• Deep Brain Stimulation: DBS is among the most expensive elective neurosurgical procedures due to the high cost of the implant hardware. In the United States, the total cost of bilateral STN-DBS implantation including the leads, IPG, extension cables, hospital stay, and surgeon fees ranges from USD 50,000–150,000. In India, equivalent surgery using the same FDA-approved Medtronic or Abbott DBS hardware costs USD 18,000–40,000, with Indian-manufactured DBS systems (Nalu, Bionik) offering further cost reduction at approximately USD 8,000–15,000.
• Stereotactic brain biopsy: Frame-based stereotactic biopsy costs USD 15,000–40,000 in the US, GBP 5,000–15,000 privately in the UK, and USD 1,500–5,000 in India. Frameless biopsy at lower-resource centres may cost even less if neuronavigation equipment is available.
• MMA embolisation for cSDH: As an emerging procedure, MMA embolisation costs USD 15,000–35,000 in the US (including the endovascular catheter laboratory fee and embolic agent cost). Where available in India and Southeast Asia, costs are typically USD 3,000–8,000.
• ETV for hydrocephalus: Endoscopic third ventriculostomy typically costs USD 20,000–50,000 in the US and GBP 6,000–18,000 privately in the UK. In India, ETV is available for USD 2,000–6,000 at accredited paediatric and adult neurosurgical centres.

For each of the major burr hole indications, evidence-based alternatives exist that may be appropriate depending on clinical circumstances and patient preference:

• Craniotomy for large or complex haematomas: For acute extradural or subdural haematomas with significant volume, organised clot, or rapid neurological deterioration, formal craniotomy rather than a burr hole provides better visualisation, haemostasis, and completeness of haematoma evacuation. Craniotomy is generally preferred for acute haematomas; burr holes are preferred for the liquid chronic collections.
• MMA embolisation alone or as adjunct for cSDH: Growing evidence supports MMA embolisation as a standalone treatment for small symptomatic cSDHs or as an adjunct after surgical drainage to reduce recurrence rates. EMBOLISE RCT (UK) and equivalent trials will provide high-quality evidence comparing embolisation with surgery over the next few years. Where available, MMA embolisation as an adjunct to burr hole drainage is increasingly considered, particularly for patients at high risk of recurrence.
• Conservative management for small cSDH: Asymptomatic or minimally symptomatic small cSDHs (maximal thickness under 10mm, no midline shift) in patients without anticoagulation may be managed conservatively with serial CT imaging, analgesia, and optimisation of bleeding risk (anticoagulant reversal or dose reduction). The majority of small cSDHs resolve spontaneously without surgery.
• Ventriculoperitoneal (VP) shunt for hydrocephalus: Where ETV is predicted to have a low success rate (ETVSS below 40%, as in communicating hydrocephalus in very young infants or post-haemorrhagic states), VP shunt insertion is the preferred treatment. The Codman Hakim programmable valve allows non-invasive adjustment of opening pressure using an external magnet, reducing the need for revision surgery due to over-drainage or under-drainage.
• Focused ultrasound (FUS) for tremor: High-intensity focused ultrasound (FUS thalamotomy) is an incisionless alternative to Vim-DBS for essential tremor and tremor-dominant Parkinson's disease, performed under MRI guidance. FUS avoids surgery entirely but is currently unilateral (treating one side of the body), irreversible, and not yet suitable for bilateral tremor or for indications beyond tremor control.